The United Kingdom and the United States have forged a landmark bilateral deal that will ensure no tariffs on UK drug shipments being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the public health system. This pledge secures that tariffs on these vital products will stay at zero for a timeframe of three years.
This agreement comes after earlier statements to hike duties on patented pharmaceutical imports, with increases mentioned up to double the cost.
"This agreement between the Britain bolsters the international landscape for cutting-edge drugs and brings long-overdue equity to American-British pharmaceutical trade," a statement declared.
Commercial Significance
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the US, which is clearly the primary market for major UK drugmakers.
Statistics indicate that in the year prior to the third quarter, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This value represented a significant portion of British export trade in that span.
"This guarantee secures jobs, boosts funding and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Detailed UK Commitments
The pact includes several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double overall health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Previously, repayments were more than 20%.
Broader Context
The deal follows a long-running tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
The disagreement were intensified by arguments that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
